Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Virtual reality could help spot thinking problems in MS patients

NCT ID NCT03768648

First seen May 22, 2026 · Last updated Jun 23, 2026 · Updated 5 times

Summary

This completed study looked at 75 people with relapsing-remitting multiple sclerosis (RRMS) who were taking the medication Aubagio. The goal was to see if virtual reality tests and real-world tasks could better detect cognitive (thinking) problems in everyday life compared to standard tests. Researchers also used advanced MRI scans to examine brain structure and connections. The study did not test a new treatment but aimed to improve how cognitive issues are identified and tracked in MS.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CHU de Bordeaux - Service de neurologie

    Bordeaux, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Aubagio (teriflunomide)

What this could lead to

If successful, this could lead to better ways to detect and track cognitive problems in daily life for people with MS, using virtual reality tests.

What could go wrong

This is an observational study with no new treatment being tested. The results may not change current care, and the virtual reality tests may not prove more useful than standard assessments.

Conditions

The condition(s) this trial relates to.

autoimmune disorder of the nervous system CNS demyelinating autoimmune disease Cognitive Dysfunction demyelinating disease immune system disorder nervous system disorder Pathologic Processes relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.